Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Hims & Hers' Super Bowl ad for unapproved weight loss drugs faces backlash from health experts over safety concerns.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most Americans.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was played on Fox Sunday night, the ad — which deems obesity “America’s deadliest epidemic,